
Table of Contents

Preface	xiii
About the Editors	xv
1. Introduction: The Role of Red Blood Cell Transfusion and Other Disease-Modifying Therapies in Sickle Cell Disease	1
<i>Emmanuel J. Volanakis, MD, and Michael R. DeBaun, MD, MPH</i>	
Pathophysiology	2
Anemia	3
Ischemia-Reperfusion Injury and Vaso-Occlusion	4
Therapeutic Approaches to SCD	5
Conclusion	23
Key Points	24
References	24
2. Anemia and Its Consequences in Sickle Cell Disease	29
<i>Julia Z. Xu, MD, MScGH, and Marilyn J. Telen, MD</i>	
Diverse Causes of Anemia in Sickle Cell Disease	29
The Consequences of Anemia in SCD	38
Improving Anemia: What Is the Evidence Showing It Helps? What Does It Help?	42
Key Considerations for Treating Anemia in SCD: The Role of Blood Viscosity in SCD	47
Case Studies	48
Key Points	51
References	52

3. Transfusion Approaches and Controversies	61
<i>Shannon C. Walker, MD, and Deva Sharma, MD, MS</i>	
Types of Transfusions in SCD	62
When to Transfuse, for Patients with SCD	65
When Not to Transfuse, for Patients with SCD	72
Special Populations	76
Controversies	80
Conclusion	85
Key Points	85
References	86
4. Sickle Cell Disease and Transfusions: A Global Perspective.	93
<i>Alexandra A. Power-Hays, MD, and Russell E. Ware, MD, PhD</i>	
Factors Contributing to the Limited Supply of Safe Blood	94
Factors Contributing to Demand for Blood in LMICs	99
Blood Transfusions for Sickle Cell Disease	103
Optimizing Transfusion Practices in LMICs	107
Conclusion	114
Key Points	115
References	115
5. Automated Red Cell Exchange.	119
<i>Jose Lima, MD; Tina S. Ipe, MD, MPH; and Ravi Sarode, MD</i>	
ASFA Indications for SCD	120
Red Cell Exchange for Acute SCD Complications	120
Red Cell Exchange for Nonacute SCD Complications	122
Red Cell Exchange Goals	123
Clinical Considerations: Vascular Access	123
Technical Considerations	127
Pediatric Considerations	130
Red Cell Depletion-Exchange (or Isovolemic Hemodilution/Red Cell Exchange)	131
Adverse Events/Complications	133
Manual Exchange	135

Table of Contents

Conclusions	135
Key Points	136
References	136
6. Red Cell Alloimmunization and Immunologic Complications, Including Hyperhemolysis	141
<i>Jeanne E. Hendrickson, MD, and Ross M. Fasano, MD</i>	
Incidence and Prevalence of Red Cell Alloimmunization	142
RH Genetic Diversity and Red Cell Alloimmunization ...	146
HLA Antigen Types and Red Cell Alloimmunization ...	147
The Impact of Inflammation on Red Cell Alloimmunization	147
Other Pathways of Potential Interest in Humans with Relevance to Red Cell Alloimmunization	147
Red Cell Alloantibody Evanescence	149
Consequences of Red Cell Alloantibodies	150
Delayed Hemolytic Transfusion Reactions	150
Future Transfusion Considerations	157
Pregnancy Considerations Regarding Red Cell Alloantibodies	157
Red Cell Autoantibodies	158
HLA Alloantibodies	158
Potential Implications of Red Cell or HLA Alloantibodies for Curative Therapies	159
Conclusions	160
Key Points	160
References	161
7. Use of Molecular Diagnostics and Community Donations with Red Cell Antigen Matching to Prevent Alloimmunization	169
<i>Nirupama Singh, MD, PhD, and Stella T. Chou, MD</i>	
Risk Factors for Alloimmunization	170
Red Cell Antigen Matching	172
RH Genetic Diversity and Role in Alloimmunization ...	174
Methods for Red Cell Antigen Genotyping	175
Community Donations	178
Conclusions	180

Transfusion Support for Patients with Sickle Cell Disease

Key Points 180
References 181

8. Non-Red-Cell-Alloimmunization Complications of Transfusion in Sickle Cell Disease 185

Imo J. Akpan, MD, and Richard O. Francis, MD, PhD

Transfusional Iron Overload 186
Hyperviscosity 198
Pulmonary Complications 199
Infectious Disease Transmission 201
Nonimmune Hemolysis 207
Allergic Transfusion Reaction 208
Acute Hypotensive Transfusion Reaction 208
Febrile Nonhemolytic Transfusion Reaction 209
Transfusion-Associated Graft-vs-Host Disease 210
Key Points 211
References 211

9. Acute Multiorgan Failure in Sickle Cell Disease 219

*Foluso J. Ogunsile, MD; Jori E. May, MD; and
Radhika Gangaraju, MD, MSPH*

The History of Acute MOF in SCD 220
Defining Important Concepts 221
The Pathogenesis of MOF in SCD 222
Conditions That Trigger MOF 225
The Clinical Presentation of MOF in SCD 232
Treatment of MOF 233
Outcomes of MOF 238
Conclusion 238
Key Points 239
References 239

10. Clinical and Laboratory Infrastructure for Sickle Cell Disease Transfusion Management 245

*Jennifer Andrews, MD, MSc; Julie Kanter, MD;
Brooke B. Bartow, MD; and Marisa B. Marques, MD*

Pretransfusion Management 246
Management at the Time of Transfusion 251

Table of Contents

The Effect of Covid-19 on the Nation's Blood Supply . . .	256
Coordinated Care	256
Posttransfusion Considerations	260
Future Directions	260
Conclusion	261
Key Points	261
References	262
11. Gene and Cellular Therapies in Sickle Cell	
Disease	265
<i>Richard C. Godby, MD; Adetola A. Kassim, MD; and</i>	
<i>Julie Kanter, MD</i>	
Gene Correction and Allogeneic HSCT	266
Gene Therapy and Autologous Modified HSCT	272
Transfusion Support	277
Conclusions	278
Key Points	278
References	279
Index.	283

